revenue expectations managementWhile I am enthralled by the opportunity presented by Pg in its many applications I think it is going to take time to build the Pg deficiency market. Similarly wound caring will not likely take off until the key clinical trials are completed in Sweden (sometime 2018 at the earliest). Off label use in severe burns etc is also an opportunity but revenues will be constrained by the fact that PLI cannot legally promote off label use. Frankly, I will be happy if Pg related revenues hit $8-10M in 2017 provided the FDA approves the drug by June/July of this year. If approval comes later then revenues will be smaller.
The big jump in plasma protein revenues will likely occur in H2 2018 as Pg deficiency revenues continue to build, wound caring is fast tracked and approved and very importantly IVIG is approved by the FDA. The latter could add substantially to revenues as the inventory build up can be offloaded immediately into the market as soon as FDA approval comes thru ($150 200M??). If the FDA is slow on the trigger for both IVIG and Pg wound caring apps then the big jump in revenues will not occur until 2019.
For the revenue picture, the wild card is partnership deals. I am expecting two regional deals on 4050 to be signed with upfront $$$ in the first half of this year and another deal on Pg wound caring sometime early 2018. These deals will address financing issues and drive the sp upwards. If these deals are not signed the shorts are going to continue to have their way with the stock, regardless of favourable clinical trial results. However, I have upmost confidence that management will deliver these partnership deals and put the squeeze on Martin and his gang of shorts.